The nutritional supplements and innovative medical device company begins the adventure of its Florida-based subsidiary
PISA — PharmaNutra fly overseas. The Board of Directors of the Pisan company founded by Andrea and Roberto Lacorte in 2003 and which develops unique nutritional supplements and innovative medical devices, has in fact given the green light to the agreement which will define the development plan for PharmaNutra Usa Corpthe American company based in Florida and dedicated to marketing products in the United States.
In America, for years, the company has obtained numerous recognitions, both patent and scientific, from the medical community. In mid-September, for example, Pharmanutra USA participated in the congresso annuale della Society for the Advancement of Patient Blood Management a Phoenixin Arizona, an event that brings together international experts to discuss the promotion and implementation of Patient Blood Management globally.
Furthermore, the direct-to-consumer sales channel, active for a few months on online platforms such as Amazon e Walmartas well as on the company’s e-commerce site itself, has generated the first sales results while awaiting the start of a specific marketing activity. “The definition of the development plan is a clear step forward in the growth of business of PharmaNutra USA – said Roberto Lacorte, CEO – we are very satisfied to have undertaken this path”.
n console.log(‘Pre RCS_JS : ‘ + Date.now());n nn n n nnn nn n n n n n n nn nn n nn n n n nn nnnnn”;
function injectExternalScript(el,src){
var newScript = document.createElement(“script”);
newScript.src = src;
target.appendChild(newScript);
}
function injectInlineScript(el,text){
var newScript = document.createElement(“script”);
var inlineScript = document.createTextNode(text);
newScript.appendChild(inlineScript);
el.appendChild(newScript);
}
function injectChoiceJs(){
if(choicejs){
target = document.getElementById(‘choice-js’);
target.innerHTML = choicejs;
var scripts = target.querySelectorAll(‘script’);
for(var i=0;i
